Utilization of glucose, blood pressure, and lipid lowering medications among people with type II diabetes in the United States, 1999–2010

Jun 18, 2014Annals of epidemiology

Use of blood sugar, blood pressure, and cholesterol medicines by people with type 2 diabetes in the US from 1999 to 2010

AI simplified

Circadian Biology on OpenScience ↗PubMed ↗DOI ↗

Abstract

Usage of metformin increased from 34.8% to 53.8% among diabetes patients from 1999 to 2010.

Half of the participants taking metformin achieved glycated hemoglobin levels of less than 7.0% during 2007-2010.
Dipeptidyl peptidase-4 inhibitors were used by 7.4% of participants in 2007-2010.
Angiotensin receptor blockers and beta-blockers usage increased significantly, from 7.4% to 21.4% and 15.3% to 31.8%, respectively.
By 2007-2010, 64.7% of participants were able to achieve blood pressure control.
Statin use doubled from 1999 to 2010, with 52.2% of participants taking them by 2007-2010.

AI simplified

PURPOSE: Changes in relation to drug treatment to various control targets for diabetes were studied using the National Health and Nutrition Examination Survey, 1999-2010.

METHODS: Data on 3094 participants aged 20 years or older with diagnosed type II diabetes were analyzed. Use of medications for lowering glucose, blood pressure, and lipids in the past month was assessed by questionnaire. Data from two survey cycles were combined together to produce estimates for each 4-year period.

RESULTS: Usage of metformin increased from 34.8% to 53.8% and was the most prevalent medications during this period (P < .001), and half of subjects taking metformin could achieve glycated hemoglobin less than 7.0% in 2007-2010. Dipeptidyl peptidase-4 inhibitors were used by 7.4% of participants in 2007-2010. Usage of angiotensin receptor blockers and beta-blockers increased significantly from 7.4% to 21.4% and from 15.3% to 31.8%, respectively from 1999 to 2010 (P ≤ .001). A total of 64.7% of participants could attain blood pressure control by 2007-2010. Usage of statins doubled in 1999-2010 and 52.2% of subjects took statins by 2007-2010 (P < .001).

CONCLUSIONS: Metformin is the first-line drug for diabetes while dipeptidyl peptidase-4 inhibitors started to be used since 2007. Blood pressure control improved in 1999-2010 partly due to increased drug prescriptions. Although statins were widely used about half of the participants did not take them.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Utilization of glucose, blood pressure, and lipid lowering medications among people with type II diabetes in the United States, 1999–2010

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the circadian biology brief